

Aug 5, 2014

**Notice of Dissolution of US Equity Method Affiliate
Vivelle Ventures LLC (d/b/a Novogyne Pharmaceuticals)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; President and CEO: Hirotaka Nakatomi, hereinafter referred to as “Hisamitsu”) hereby announces the dissolution of Vivelle Ventures LLC (d/b/a Novogyne Pharmaceuticals) (Head Office: East Hanover, New Jersey, USA; hereinafter referred to as “Novogyne”), a joint venture of our US subsidiary Noven Pharmaceuticals, Inc. (Head Office: Florida, USA; hereinafter referred to as “Noven”) and Novartis Pharmaceuticals Corporation (Head Office: East Hanover, New Jersey, USA; hereinafter referred to as “Novartis”).

1. Background

Novogyne was established on April 29, 1998 as a joint venture with Novartis and will be dissolved on August 12, 2014 by agreement of Noven and Novartis.

With the dissolution of Novogyne, the ownership rights to CombiPatch[®] in the United States and to Vivelle-Dot[®] will be changed as follows.

Product name	Owner (before dissolution of Novogyne)	Owner (after dissolution of Novogyne)
Vivelle-Dot [®]	Novogyne	Novartis
CombiPatch [®]	Novogyne	Noven

* The manufacturer of the above products will continue to be Noven before and after the dissolution of Novogyne.

2. Impact on Hisamitsu

Novogyne is an equity-method affiliate of Hisamitsu, and at present, the profits of Novogyne are posted as non-operating income in the consolidated income statement, but this non-operating income will no longer be posted after the dissolution of Novogyne. Furthermore, as explained in 1. Background, with the change in the distributors of the products affected, Hisamitsu's net sales and various forms of income on the consolidated income statement will be affected.

The effect of this matter on Hisamitsu's consolidated performance will be minor, and no changes have been made to the performance forecast for this period.

About Noven

Noven is a pharmaceutical company engaged in research, development, manufacturing, marketing, and sale of pharmaceutical products. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, its customers, and its industry partners. Noven is a subsidiary of Hisamitsu and serves as Hisamitsu's U.S. growth platform.